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Poster Session II S275response. Genomic technologies can identify molecular subgroups
with distinct genomic signatures. We investigated the genomic
changes in patients with AML undergoing HCT using DNA mi-
croarrays. We analyzed 11 patients before HCT and at relapse after
HCT, 6 patients had a normal karyotype at diagnosis and 5 had ab-
normal karyotype with different types of aberrations. After high
resolution of whole genome DNA profiling analysis 5 of the 6 pa-
tients with normal karyotype showed genomic aberrations (GA) in
the form of gains and losses (5/5 gains/losses) in several regions of
different chromosomes with a median of 2 GA per case. The ab-
normal karyotype group, in addition to the cytogenetically detected
aberrations GA were present in 2 out of 5 patients (5/4 gains/los-
ses). Overall 64% of the patients had GA, not detected by conven-
tional cytogenetics. All FAB subtypes of AML showed GA, being
M5 and secondary AML both with more numerous GA (average:
12 and 17 GA respectively). At relapse 6 patients increased the
number of GA, (median of 7 GA per case), while 3 patients pre-
sented a reduced number of GA (median 2 GA per case). The re-
maining 2 patients showed no additional changes. Before
transplantation 16 chromosomes showed GA with a median of 3
GA per chromosome, average size of gains and losses were 1568
and 8046 kb respectively. At relapse 19 chromosomes had GA
with a median of 4 GA per chromosome, average size of gains
and losses were 697 and 8011 kb respectively. Chromosomes 11,
14 and 21 showed no GA at any time point. Our preliminary
data demonstrate that AML is a genomically heterogeneous disease
with a high incidence of small non recurrent DNA GA that can be
detected even in cases with normal karyotype. Cryptic genomic
changes are likely to play a role in relapse after allogeneic trans-
plantation.315
CLADRIBINE (2CDA) IS COMPARABLE TO FLUDARABINE IN A BUSULFAN-
BASED REDUCED- INTENSITY REGIMEN
Yakushijin, K., Fukuda, T., Asakura, Y., Kurosawa, S., Hiramoto, N.,
Tada, K., Nishinohara, M., Maeda, T., Hagiwara, A., Ueno, N.,
Kamiyama, Y., Mori, M., Kim, S.-W., Mori, S., Tanosaki, R.,
Heike, Y., Takaue, Y. National Cancer Center Hospital, Tokyo, Japan
Reduced-intensity stem cell transplantation (RIST) with a purine
analog most often involves fludarabine (Flu). The alternative drug,
2CdA, is rarely used partly because of a potential risk of renal
toxicity. We retrospectively reviewed the medical records of 282
patients (median age, 54 y; range, 21-68) with various hematolog-
ical malignancies who underwent RIST between 1999 and 2007
with a conditioning regimen that consisted of busulfan (po 8 mg/
kg or iv 6.4 mg/kg) in combination with either 2CdA (0.66 mg/
kg, n5 71, C-group) or Flu (180 mg/m2, n5 211, F-group). Se-
venty-four patients also received 2-4 Gy of TBI. The donor was re-
lated (BM 8, PB 177) in 185 patients, and unrelated in 97 (BM 79,
PB 1, CB 17). GVHD prophylaxis consisted of cyclosporine (CSP,
starting dose 3 mg/kg/day civ, target whole blood conc. 250-350
ng/ml, n5 232) or tacrolimus (starting dose 0.03 mg/kg/day civ,
target whole blood conc. 10-20 ng/ml, n5 50), with (n5 131) or
without (n5 151) MTX. Sixty-nine patients also received anti-hu-
man T- lymphocyte immunoglobulin (ATG, 5-10 mg/kg). Except
for the stem cell sources, there were no significant differences be-
tween the C- and F-groups. Acute renal failure (ARF) within 100
days was defined as there was a greater than two-fold rise in the se-
rum creatinine concentration compared to the baseline. The me-
dian follow-up in surviving patients was 1589 days (50-3291).
The 275 patients who survived more than 30 days (except for
one patient who died of relapse) all achieved neutrophil engraft-
ment in a median 13 days (range, 5-42 days). No significant differ-
ence was observed between C- and F-group with regard to OS
(59% vs 48% at 3 y, p5 0.20), relapse rate (42% vs 35% at 3 y,
p5 0.42), NRM (7% vs 6% on d100, 22% vs 32% at 3 y,
p5 0.15), or the cumulative incidences of ARF (34% vs 27% on
d 100, p5 0.26), grade II-IV acute GVHD (46% vs 47%,
p5 0.40), and extensive chronic GVHD (62% vs 54% at 3 y,
p5 0.21). Multivariate analyses showed that TBI [HR 2.96 (1.86-
4.72), p\0.001] for NRM, TBI [HR 1.75 (1.23-2.49), p5 0.002]and high-risk disease [HR 2.39 (1.62-3.55), p\0.001] for OS,
and TBI [HR 1.98 (1.25-3.14), p5 0.004] and CSP [HR 2.10
(1.06-4.17), p5 0.03] for ARF were significant factors for poor
outcomes. However, 2CdA was not significantly associated with
NRM, OS or ARF. Our study suggested that a relatively low
dose of 2CdA was tolerable and feasible as part of a reduced-
intensity regimen, and was not associated with any significant
nephrotoxicities.316
TANDEM AUTO-ALLO IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS IN
FIRST COMPLETE REMISSION (CR)
Castagna, L.1, Prebet, T.1, Fu¨rst, S.1, El-Cheikh, J.1, Charbonnier, A.1,
Faucher, C.1, Mohty, M.2, Chabannon, C.3, Vey, N.1, Blaise, D.1 1 Institut
Paoli Calmettes, Marseille, France; 2 Hotel Dieu, Nantes, France; 3 Institut
Paoli Calmettes, Marseille, France
Background: High and intermediate risk AML can benefit from
allo-SCT in first CR. Reduced intensity conditionings (ALLO-
RIC) decreases toxicity. However there are now data in favour of
lower disease control as compared with standard CDT.We hypoth-
esized that if a better quality of remission could be achieved, the re-
lapse incidence could be lowered.
Patients and methods: From 2001 to 2008, 31 AML patients in
first CR received a tandem auto-allo program. At diagnosis, me-
dian number of WBC was 3  10e9/l (0.9-235), 13% of patients
have extramedullary localisations. 64% of patients were considered
at high-risk (cytogenetic, secondary disease or double inductions)
and 36% at intermediate risk. After reaching CR1, all but two pa-
tients received a consolidation course with high-dose cytarabine
(HD-ARAC, 24 g/m2 in 93%) CT, followed by autologous stem
cell harvest. HD melphalan (HD-PAM 140 mg/m2) was followed
by autologous stem cells reinfusion. Then, ALLO-RIC consisted
of fludarabine (90 mg/m2) plus (2 Gy) TBI (3 pts) or fludarabine
(150 mg/m2), busulfan over 2 days, and thymoglobuline (2.5 or
5 mg/kg). GVHD prophylaxis was CyA. 3 patients received also
mycofenolate mofetil. All donors, but one, were HLA identical
sibling. The median number of allo CD34+ cells was 6.1 
10e6/Kg. Prognostic scores (HCT-CI, PAM, EBMT) were retro-
spectively calculated for each patient. All pts have a performance
status$ 90%.
Results:Median fup from diagnosis and ALLO-RICwere 40 and 34
months, respectively. Median days between last CT and HD-PAM
was 51 (30-77) and between HD-PAM and ALLO-RIC was 69
(55-176). 5 pts relapsed for a 4 year CI of 15% (3-29). At last fup,
13 have died (relapse: 5; toxicity: 8). Grade II-IV aGVHD and
cGVHD CI were respectively 26% and 65% (extensive 84%).
GVHD was the cause of death in seven pts. Six pts (19%) reactived
CMV, and 1 pt did not survive to an interstitial pneumonitis. The
4-year overall survival (OS), relapse free survival (RFS), and 1-year
TRMwere 61% (43-76), 59% (41-75), and 16% (3-29), respectively.
In multivariate analysis, prognostic scores did not influence TRM
and OS.
Conclusions:This report showed that i) tandem auto-allo is feasible
in AML pts; ii) acute GVHD incidence is not increased; iii) prognos-
tic scores did not impact on TRM and survival; iv) TRM is low with
GVHDasmain cause of death; v) low relapse rate is documented and
invites further development.317
LONG TERM OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTA-
TION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
El-Emary, M.1, Al Khabori, M.1, Buitron, N.1, Messner, H.1, Lipton, J.1,
Gupta, V.1, Kuruvilla, J.1, Xu, W.2, Galal, A.1 1 Princess Margaret Hos-
pital, University of Toronto, Toronto, ON, Canada; 2 Princess Margaret
Hospital, University of Toronto, Toronto, ON, Canada
Introduction: Allogeneic Stem Cell Transplantation (Al-SCT) re-
mains an option for patients with advanced Chronic Lymphocytic
Leukemia (CLL) with high risk features.
S276 Poster Session IIMethods:We performed a retrospective analysis of our patients
with CLL/Pro-lymphocytic leukemia (PLL) who underwent Al-
SCT at our center between August 1989 and February 2009.
The objective of this study is to evaluate the overall survival
(OS), relapse free survival (RFS), acute and chronic graft versus
host disease (aGVHD, cGVHD). We also compared the inten-
sity of conditioning regimens (conventional: CIC Vs reduced:
RIC), donor type, (matched sibling: MSD vs matched unre-
lated: MUD), graft source (bone marrow: BM vs peripheral
blood: PB) and their impact on OS, RFS, aGVHD and
cGVHD.
Results:There are 59 patients available for review. Patients char-
acteristics are listed in table 1. There were a variety of condition-
ing regimens; for the CIC, 36 pts. received Busulfan based
regimens and 10 pts. Total Body Irradiation based regimens, for
the RIC 13 pts. received different fludarabine based regimens.
Donor types were 48 MSD and 11 MUD. Source was BM in
27 and PB in 32 pts. Most (43/59 pts) received CyA-MTX as
the GvHD prophylaxis but 12 and 4 pts. received Mycophenolate
and Campath with CyA respectively. The median follow up is 45
months (7-237). The median survival time is 115 months with a 5
year survival probability of 57% (95% CI: 0.43-0.68). OS was not
statistically significantly different when comparing type of condi-
tioning or graft source, however a significant improvement in
OS with MSD type over MUD, (P value5 0.0007). The 3-year
RFS is 48% (95% CI: 0.35-0.60) with no statistically significant
difference according to regimen intensity and graft source, with
a significant superior outcome for MSD Vs MUD (P val-
ue5 0.002). Grade 2-4 aGvHD was seen in 40 cases. The cumu-
lative rates of aGvHD 2-4 are not different between the
conditioning, donor type and graft source. Forty-one cases
(68%) experienced cGvHD (18% limited,50% extensive) with no
difference according to regimen intensity and donor type, al-
though a significantly increased incidence in the PB group (P val-
ue5 0.03). Causes of death include infection (40%), GVHD
(33%), relapse (18%) and VOD (9%).
Conclusions: Acceptable survival post Al-SCT is possible in CLL
although TRM is significant. This retrospective analysis demon-
strates inferior survival for MUD recipients and similar outcomes
when comparing RIC and CIC regimens.
Table 1. Patients characteristicsPts studied , n. 59
Diagnosis : CLL / PLL 54 / 5
Mean age (range), y 46 (27-67)
Gender (F /M), n. 19 / 40
Number of prior regimens, mean (range) 4 (1-9)
Prior Purine analogue 84 %
Prior Rituximab 11 %318
OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
CHILDREN WITH SEVERE APLASTIC ANEMIA. TEN YEARS EXPERIENCE
IN A LARGE PEDIATRIC TRANSPLANT CENTRE
Zaidman, I.1, Schecter-Finkelstein, T.2, Doyle, J.2, Gassas, A.2 1 Rambam
Health Care Campus, Haifa, Israel; 2 Hospital for Sick Children, Toronto,
ON, Canada
Severe aplastic anemia (SAA) in children is a rare and serious dis-
ease. The best potential cure is allogeneic hematopoietic stem cell
transplantation (SCT). Our objective herein was to review the out-
come of all children who received SCT for a diagnosis of SAA be-
tween 1998-2008 in the Hospital for Sick Children, Toronto.
Fifty-eight children were included in the study. Median age at
SCT was 10.1 years (range 1.6-17 yrs). Median time from diagnosis
to SCT was 8.8 months (range 1-142 months). Stem cell source was
related in 38; living unrelated in 18 and 2 patients received cord pro-
genitor stem cells.
Twenty-seven patients received immunosuppressant therapy
prior to SCT. Conditioning regimen for the related donors in-cluded cyclophosphamide and antithymocyte globulin (ATG).
For the unrelated, either a single dose total body irradiation
(TBI) 200 cGy or fludarabine was added. Overall survival for
the whole group was 84%. In a univaraite analysis, factors af-
fecting survival were: stem cell source (related 90%; unrelated
71%); type of SAA (idiopathic 90%; post hepatitis or drug re-
lated 70%; possible hereditary 60%); previous immunossupres-
sive therapy and multiple transfusions (of 10 patients who
died, 8 were treated with 1 or 2 courses of immunossupressive
therapy and 6 of them had more than 20 blood transfusions be-
fore SCT).
Incidence of acute and chronic graft-versus host disease (GVHD)
were 29% and 14% respectively with 6 out of 8 patients with chronic
GVHDwere recipient of unrelated donors. Ten patients died due to
transplant related mortality (TRM) and seven were recipient of un-
related donors. Causes of death were: sepsis, severe VOD, CMV in-
fection and multiorgan failure.
Long term chimerism testing showed 54% of the patients con-
tinued to have full donor status, 22% are stable mixed chimerism
and 4% with decreased chimerism; 15% suffered engraftment fail-
ure (5%-primary and 10%-secondary) and 5% of patients died be-
fore engraftment and were not evaluable for engraftment. Of the 9
patients with primary and secondary graft failure 6 had unrelated
donor.
In conclusion: Our results suggest that factors affecting prognosis
of children with SAA treated with SCT are: etiology of SAA, previ-
ous immunosuppressant therapy, multiple transfusions and type of
donor. Furthermore, engraftment failure continues to be a problem
in particular for recipient of unrelated donors.319
RELATION OF TNFA, TNFB AND TNFRII GENE POLYMORPHISMS TO OUT-
COMES AFTER UNRELATED HAEMATOPOIETIC CELL TRANSPLANTATION
WITHIN CHINESE POPULATION
Xiao, H., Lai, X., Wu, G., Luo, Y., Shi, J., Tan, Y., Han, X., Zhu, X.,
Zhu, J., Xie, W., He, J., Cai, Z., Lin, M., Ye, X., Huang, H. The First
Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,
Zhejiang, China
Background: The genes code TNFa (TNFA), TNFb (TNFB) and
TNF receptor II (TNFRII) contain multiple single nucleotide poly-
morphisms (SNPs). The present study was designed to test associa-
tion of these genes polymorphisms with outcomes after unrelated
HSCT within Chinese population.
Methods: A total of 138 pairs of donors and recipients, who
had undergone HSCT from 2001 to 2009 at our center, were
tested for TNFA-1031(T.C), -863(C.A), -857(C.T),
-238(G.A), TNFB + 252(A.G) and TNFRII codon 196
(T.G) genotypes.
Results: (1) Recipients and/or donors with TNFA-857 C/C geno-
type or TNFB + 252 G allele-positive had a higher incidence of
aGVHD (P\0.05). TNFRII 196 T/T genotype in donors side
or recipients side showed a stronger trend toward development of
aGVHD (in donor side: P5 0.028; in recipient side: P5 0.086).
When these effects were analyzed only in 96 pairs of HLA matched
cases, donor and/or recipient TNFA-857 and TNFB + 252 geno-
type also affected aGVHD incidence. The influence of TNFRII
genotype was not significant except the recipient type showed
a trend (P5 0.074).The genotypes of TNFA -1031, -863 and
-238 were not found to be associated with the risk of aGVHD.
(2) TNFA-857, TNFB + 252 and TNFRII 196 polymorphic fea-
tures, together with other factors were subjected to multivariate
analysis for aGVHD. Myeloablative conditioning(RR5 3.771,
P5 0.004), donor with TNFA-857C/C genotype (RR5 2.29,
P5 0.006) and recipient with TNFB + 252 G allele-positive
(RR5 1.789, P5 0.036) were found to significantly contribute to
the development of aGVHD. Donor-recipient gender was found
to be a less significant factor (P5 0.079). As to grade II-IV
aGVHD, myeloablative conditioning (RR5 3.929, P5 0.022),
HLA mismatching (RR5 1.691, P5 0.048) and donor with
TNFA-857 C/C genotype (RR5 3.748, P5 0.002) were found to
